p.71 抽出テキスト

CLINICAL STATEMENTS AND GUIDELINES

Circulation. 2024;149:e1313–e1410. DOI: 10.1161/CIR.0000000000001251 June 11, 2024 e1383

13 Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2018 an-

nual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2019;73:A7-A8. 14.	 Luders F, Bunzemeier H, Engelbertz C, et al. CKD and acute and long-term outcome of patients with peripheral artery disease and critical limb ischemia. Clin J Am Soc Nephrol. 2016;11:216–222. 15.	 Hopley CW, Kavanagh S, Patel MR, et al. Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: the EUCLID trial. Vasc Med. 2019;24:422–430. 16.	 Bourrier M, Ferguson TW, Embil JM, et al. Peripheral artery disease: its adverse consequences with and without CKD. Am J Kidney Dis. 2020;75:705– 712. 17.	 Behroozian A, Beckman JA. Microvascular disease increases amputation in patients with peripheral artery disease. Arterioscler Thromb Vasc Biol. 2020;40:534–540. 18.	 Olesen KKW, Anand S, Thim T, et al. Microvascular disease increases the risk of lower limb amputation - A Western Danish cohort study. Eur J Clin Invest. 2022;52:e13812. 19.	 Beckman JA, Duncan MS, Damrauer SM, et al. Microvascular disease, peripheral artery disease, and amputation. Circulation. 2019;140:449–458. 20.	 Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation. 2022;145:e153–e639. 21.	 Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180–189. 22.	 Bhatt DL, Peterson ED, Harrington RA, et al. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J. 2009;30:1195–1202. 23.	 Gutierrez JA, Mulder H, Jones WS, et al. Polyvascular disease and risk of major adverse cardiovascular events in peripheral artery disease: a secondary analysis of the EUCLID trial. JAMA Netw Open. 2018;1:e185239. 24.	 Chen DC, Singh GD, Armstrong EJ, et al. Long-term comparative outcomes of patients with peripheral artery disease with and without concomitant coronary artery disease. Am J Cardiol. 2017;119:1146–1152. 25.	 Olivier CB, Mulder H, Hiatt WR, et al. Incidence, characteristics, and outcomes of myocardial infarction in patients with peripheral artery disease: insights from the EUCLID trial. JAMA Cardiol. 2019;4:7–15. 26.	 Serena J, Segura T, Roquer J, et al. The ARTICO study: identification of patients at high risk of vascular recurrence after a first non-cardioembolic stroke. BMC Neurol. 2015;15:28. 27.	 Bonaca MP, Gutierrez JA, Cannon C, et al. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol. 2018;6:934–943. 28.	 Li MF, Zhao CC, Li TT, et al. The coexistence of carotid and lower extremity atherosclerosis further increases cardio-cerebrovascular risk in type 2 diabetes. Cardiovasc Diabetol. 2016;15:43. 29.	 Gutierrez JA, Scirica BM, Bonaca MP, et al. Prevalence and outcomes of polyvascular (coronary, peripheral, or cerebrovascular) disease in patients with diabetes mellitus (from the SAVOR-TIMI 53 trial). Am J Cardiol. 2019;123:145–152. 30.	 Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391:219– 229. 31.	 Bauersachs RM, Szarek M, Brodmann M, et al. Total ischemic event reduction with rivaroxaban after peripheral arterial revascularization in the VOY- AGER PAD trial. J Am Coll Cardiol. 2021;78:317–326. 32.	 Low Wang CC, Blomster JI, Heizer G, et al. Cardiovascular and limb outcomes in patients with diabetes and peripheral artery disease: the EUCLID trial. J Am Coll Cardiol. 2018;72:3274–3284. 33.	 Collins AJ, Foley RN, Chavers B, et al. United States Renal Data System 2011 Annual Data Report: atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis. 2012;59:A7, e1-420. 34.	 Rajagopalan S, Dellegrottaglie S, Furniss AL, et al. Peripheral arterial disease in patients with end-stage renal disease: observations from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Circulation. 2006;114:1914–1922. 35.	 McDermott MM, Guralnik JM, Tian L, et al. Incidence and prognostic significance of depressive symptoms in peripheral artery disease. J Am Heart Assoc. 2016;5:e002959. 36.	 Arya S, Lee S, Zahner GJ, et al. The association of comorbid depression with

mortality and amputation in veterans with peripheral artery disease. J Vasc Surg. 2018;68:536–545.e2. 37 Cherr GS, Wang J, Zimmerman PM, et al. Depression is associated with

worse patency and recurrent leg symptoms after lower extremity revascularization. J Vasc Surg. 2007;45:744–750. 38.	 Kuruppu S, Ghani M, Pritchard M, et al. A prospective investigation of depression and adverse outcomes in patients undergoing vascular surgical interventions: a retrospective cohort study using a large mental health database in South London. Eur Psychiatry. 2021;64:e13. 39.	 Thomas M, Patel KK, Gosch K, et al. Mental health concerns in patients with symptomatic peripheral artery disease: insights from the PORTRAIT registry. J Psychosom Res. 2020;131:109963. 40.	 Smolderen KG, Hoeks SE, Pedersen SS, et al. Lower-leg symptoms in peripheral arterial disease are associated with anxiety, depression, and anhedonia. Vasc Med. 2009;14:297–304. 41.	 Lyness JM, Noel TK, Cox C, et al. Screening for depression in elderly primary care patients. A comparison of the Center for Epidemiologic Studies- Depression Scale and the Geriatric Depression Scale. Arch Intern Med. 1997;157:449–454. 42.	 Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999;282:1737– 1744. 43.	 Allison MA, Armstrong DG, Goodney PP, et al. Health disparities in peripheral artery disease: a scientific statement from the American Heart Association. Circulation. 2023;148:286–296. 44.	 Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317– 1324. 45.	 Willigendael EM, Teijink JA, Bartelink ML, et al. Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg. 2004;40:1158–1165. 46.	 Elbadawi A, Elgendy IY, Megaly M, et al. Temporal trends and outcomes of critical limb ischemia among patients with chronic kidney disease. Vasc Med. 2021;26:155–163. 47.	 Arhuidese I, Nejim B, Locham S, et al. Infrainguinal bypass surgery outcomes are worse in hemodialysis patients compared with patients with renal transplants. J Vasc Surg. 2019;69:850–856. 48.	 Smilowitz NR, Bhandari N, Berger JS. Chronic kidney disease and outcomes of lower extremity revascularization for peripheral artery disease. Atherosclerosis. 2020;297:149–156. 49.	 Nejim B, Hicks CW, Arhuidese I, et al. Outcomes of infrainguinal lower ex-

tremity bypass are superior in kidney transplant recipients than patients with dialysis. Ann Vasc Surg. 2020;63:209–217. 4.2. Health Disparities in PAD 1.	 Lefebvre KM, Chevan J. The persistence of gender and racial disparities in vascular lower extremity amputation: an examination of HCUP-NIS data (2002-2011). Vasc Med. 2015;20:51–59. 2.	 Allison MA, Armstrong DG, Goodney PP, et al. Health Disparities in Peripheral Artery Disease: A Scientific Statement From the American Heart Association. Circulation. 2023;148:286–296. 3.	 Minc SD, Hendricks B, Misra R, et al. Geographic variation in amputation rates among patients with diabetes and/or peripheral arterial disease in the rural state of West Virginia identifies areas for improved care. J Vasc Surg. 2020;71:1708–1717.e5. 4.	 Hurst JE, Tehan PE, Hussey K, et al. Association of peripheral artery disease and chronic limb-threatening ischemia with socioeconomic deprivation in people with diabetes: a population data-linkage and geospatial analysis. Vasc Med. 2021;26:147–154. 5.	 Arya S, Binney Z, Khakharia A, et al. Race and socioeconomic status independently affect risk of major amputation in peripheral artery disease. J Am Heart Assoc. 2018;7:e007425. 6.	 Barnes JA, Eid MA, Creager MA, et al. Epidemiology and risk of amputation in patients with diabetes mellitus and peripheral artery disease. Arterioscler Thromb Vasc Biol. 2020;40:1808–1817. 7.	 Mustapha JA, Fisher BT Sr, Rizzo JA, et al. Explaining racial disparities in amputation rates for the treatment of peripheral artery disease (PAD) using decomposition methods. J Racial Ethn Health Disparities. 2017;4:784– 795. 8.	 Carnethon MR, Pu J, Howard G, et al. Cardiovascular health in African Americans: a scientific statement from the American Heart Association. Circulation. 2017;136:e393–e423. 9.	 Holman KH, Henke PK, Dimick JB, et al. Racial disparities in the use of

revascularization before leg amputation in Medicare patients. J Vasc Surg. 2011;54:420–426, 426.e1.

Downloaded from http://ahajournals.org by on October 7, 2026